SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NARI, QTRX, CTV on Behalf of Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2025
0mins
Source: PRnewswire
Investigation of Companies: Halper Sadeh LLC is investigating Inari Medical, Quanterix Corporation, and Innovid Corp for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.
Legal Support for Shareholders: The law firm offers free consultations to shareholders affected by these transactions, aiming to seek increased compensation or other benefits on a contingency fee basis.
Analyst Views on QTRX
Wall Street analysts forecast QTRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 7.950
Low
5.00
Averages
6.00
High
7.00
Current: 7.950
Low
5.00
Averages
6.00
High
7.00
About QTRX
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
